Capricor BLA amendment for Deramiocel leads FDA to extend review, Nov. 22, 2026 PDUFA date

 

• Reported Q3 2026 loss of $0.73 per share, missing analyst consensus estimate for a $0.61 loss.
• Q3 2026 net loss totaled $42.7 million for the period.
• Ended Q3 2026 with $198.5 million in cash to support operations.
• Announced a 10% workforce reduction in conjunction with reporting Q3 2026 financial results.

https://finviz.com/stock?t=CAPR&p=d